公众号 / 文章重症综合管理与镇静镇痛消化、代谢与肾脏急症

ICU患者个体化血糖控制:证据与临床实践

Individualising blood glucose control in ICU patients: evidence and practical implementations.
PubMed 文献 · Crit Care · 2026-09-09
一句话结论ICU高血糖管理取决于营养策略与控糖方案质量:避免严重高血糖和低血糖,无验证方案时默认中间目标。

本文综述了ICU患者个体化血糖控制的证据与临床实践。 landmark RCTs提示将血糖降至健康年龄调整空腹范围的强化控糖效果取决于控糖方案的准确性和营养策略。早期肠外营养诱导严重医源性高血糖时,强化控糖显著降低并发症和死亡率;无早期肠外营养时高血糖较轻,采用避免严重低血糖的计算机化方案强化控糖对死亡率无影响,但部分并发症获益减弱;而严重低血糖风险高的方案则增加死亡率。总体应避免严重医源性高血糖和低血糖,无验证方案时默认中间血糖目标。

要点

  • 早期肠外营养诱导严重医源性高血糖时,强化控糖可显著降低并发症和死亡率。
  • 无早期肠外营养时高血糖较轻,采用避免严重低血糖的计算机化方案强化控糖对死亡率无影响。
  • 使用显著增加严重低血糖风险的控糖方案与死亡率增加相关。
  • 总体应避免严重医源性高血糖和低血糖,无验证方案时默认中间血糖目标。
  • 建议根据临床背景采用不同的血糖目标,未来需研究个体化目标是否改善患者结局。

适用人群与场景

  • ICU患者,尤其出现高血糖者
  • 营养策略涉及早期肠外营养者

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体药物剂量,仅建议根据临床背景采用不同血糖目标
  • 无验证避免严重低血糖方案时,默认中间血糖目标

红旗征与不能漏的情况

  • 严重医源性高血糖
  • 严重低血糖

研究设计与关键结果

  • 综述landmark RCTs:早期肠外营养条件下强化控糖显著降低并发症和死亡率;无早期肠外营养时计算机化强化控糖对死亡率无影响,部分并发症获益减弱;严重低血糖风险高的方案增加死亡率

证据类型、等级与局限

  • 综述,证据来自landmark RCTs
  • 局限性:部分机制未证实,需前瞻性研究验证个体化目标

对床旁实践的改变

  • 强调根据营养策略和控糖方案质量个体化血糖管理,避免严重高血糖和低血糖;无验证方案时采用中间目标

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

Many intensive care unit patients develop hyperglycaemia, and this is associated with an increased risk of adverse outcomes. Landmark randomised controlled trials (RCTs) suggest the impact of lowering blood glucose to the healthy, age-adjusted fasting range, hereafter called tight glucose control, depends on the accuracy of the glucose control protocol and the nutritional strategy. In the context of early parenteral nutrition, a condition that induces severe, iatrogenic hyperglycaemia, tight glucose control significantly reduced morbidity and mortality compared to tolerating severe hyperglycaemia. In the absence of early parenteral nutrition, hyperglycaemia was less severe; tight glucose control, applied with a computerised protocol that avoided severe hypoglycaemia, did not impact mortality nor the duration of ICU dependency as primary endpoint in a large multicentre RCT, but was associated with a less pronounced benefit on selected morbidity outcomes. Conversely, tight glucose control, using a protocol that considerably increased the risk of severe hypoglycaemic events, concomitantly increased mortality; nevertheless, the cause of excess mortality in this trial remains unproven and other mechanisms may have contributed as well. Altogether, evidence suggests that severe and iatrogenic hyperglycaemia and hypoglycaemia should both be avoided. From a pathophysiologic point of view, tight glucose control may be superior in selected settings if it can be applied with a validated protocol that avoids severe hypoglycaemia. In the absence of such a protocol, the increased risk of severe hypoglycaemia may offset any benefit of preventing hyperglycaemia, and tolerating intermediate blood glucose targets is likely the default setting. In the paper, we suggest specific blood glucose targets that differ according to the clinical context. Future research should aim at strategies that further optimise the quality of blood glucose control and study whether these improve patient-centred outcomes, and investigate whether specific patient populations benefit from individualised targets.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Gunst J, Krinsley JS, Lanspa MJ, et al. Individualising blood glucose control in ICU patients: evidence and practical implementations. Crit Care. 2026. PMID: 42745269. doi:10.1186/s13054-026-06288-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。